All right. Thanks for coming back after lunch. My name is Andy Chen. I'm one of the CAR T physicians at OHSU.
And we're going to be talking about Car-T this afternoon. These are my disclosures. These are the companies I'm involved with on clinical trials and consultant for a couple of them.
So what we want to go over is how Car-T works. Who is a good candidate and when to consider Car-T? Also how the process actually works. From the time we collect your cells through the procedure itself and the initial month and then longer term follow up afterwards. And then I'll also mention some about how does Car-T fit in comparison to traditional stem cell transplant, as well as bispecific antibodies? That's an ongoing area of controversy.
So what is CAR T-cell therapy? So T cells are lymphocytes. And so they're normally part of your immune system. There are type of white cell that helps fight infection. A CAR, not a Honda, is a chimeric antigen receptor. And what that is, is it. It's a synthetic construct. Where on the outside, it targets the T cell to the myeloma. There's a binding, what we call it. There's an outside where it binds, and then there's an inside part where it activates the T cell after it binds the target. It's a chimera because they basically took parts of different molecules and mashed them up together. Remember from Greek mythology, the Chimera, I think, was part lion, part dragon. There's a third one. I don't remember what the third part was.
But, that's what it is. And then what you end up with is a CAR T cell. And so the idea is that the Car T-cell has now been genetically modified so that it recognizes the myeloma cell. And then the inside part of the then activates the T cell. And the T cell is a lymphocyte that normally goes around and fights infections. And then it uses that infection fighting machinery to then kill the myeloma cell. So that's the idea. So it's a way of using your immune system. This is an immune type therapy. So what we call an immune effector cell.
So this is sort of the grand overview from the patient perspective. So the first thing that will happen is that there is a collection where we collect your T cells and we just collect them from your blood. Those of you who had stem cell transplant, it's similar idea just without the growth factor shots. And then we collect the T cells and send them off to the manufacturer. And then the manufacturer grows up, isolates the T cells, genetically modifies them and then grows them up and then tests them, make sure they're, you know, that they're working well and they pass all the quality standards. That takes roughly 3 to 4 weeks. During that period, you may get additional therapy to keep your myeloma under control while you're waiting for the cells to come back.
And then when it's time for the cells to come back, then you would you get a low dose of chemotherapy for a few days. And that chemotherapy is really not intended to treat the myeloma. It's really to knock down your immune system so that there's room for the car T cells to expand. And then you get the T cells and it's, you know, it's a bag of frozen cells and it's just a smaller volume than a transplant. If people have had that and then you get monitored very, very carefully for the first month, especially the first two weeks, because, car T works very well, but there are definite risks and side effects that can come along with it.
So, car T has been a rapidly growing field. So, when we did our, you know, first clinical trials with Car-T, they were in lymphoma and acute leukemia. And this was around 2016 ish time frame. And then we did our first commercially available Car-T and lymphoma about a year, year and a half later. And that first year we did maybe five or so. And then you can see the sort of exponential growth of car T during that time and myeloma. Carvykti came along in the past few years, the the development was a little bit later than what we saw with lymphoma. There are over 800 different cell therapy products and clinical development around the world. That's a rough estimate according to Google. But it's a very I there's, you know, the the other thing is that autologous transplant, the numbers of auto transplant has actually been flat to declining for the past several years.
And these numbers have, you know, are across the United States as well as around the world.
So where is the role of CAR T in myeloma? So the first thing is what is it actually. Can you get it for because, Car-T is a very involved process. So you can only do it where it's actually you can't just decide you want to do it from the start. You can't decide you want to do it for, you know, smoldering myeloma. It's only approved in the United States. And the relapse setting, when it first came out, it had to be after you had 3 or 4 lines of therapy. Since then, there have been large randomized clinical trials showing that Car-T is more effective than traditional standard therapies. And so now we can use it after early in earlier lines of therapy. So like at first or second relapse, there are two commercially available Car-T products in the United States.
I say current because there's a lot of hope that there may be another product that will be approved in the near future, and maybe possibly two. So the one that's most commonly used is called carb. And because medicine is very we like being complicated. It's also called ciltacabtagene autoleucel, which is too long to say. So everyone just calls it cilta-cel. But Carvykti is the brand name that you will see most often out there. The other product out there is called Abecma. It's also called idecabtagene or ide-cel. And the difference between the two, the biggest difference is how they bind the target myeloma cell. That's the biggest difference. The approvals are also somewhat different for you have to have received at least one prior therapy.
And that includes what we call a proteasome inhibitor. The most common one you guys probably are aware of is bortezomib or Velcade. And then what we call an IMiD or immunomodulatory agent, lenalidomide and Revlimid is the most common one that's used early. So and the other thing is that you have to be resistant to Revlimid where you have to have received at least two prior therapies and what we call an anti-CD38 antibody. So that's there are two, also known as Darzalex. Isatuximab is the other one that's out there. So the approval is slightly different. And you have to meet these criteria. Otherwise you won't get it paid for by insurance. And unless you're one the person who won that lottery earlier this week, it's quite expensive.
Try to swing it on your own. Oh. Same slide. Sorry. So how well does CAR T work in myeloma? So generally speaking, Carvykti appears there have never been a randomized study head to head between and and but when you look across studies and look in sort of the retrospective analyses, Cod generally seems to be somewhat more effective. The typical remission. The emphasis is typical is roughly three or more years. So in the original studies it looks like the average is roughly around three years. But those were patients who were more heavily pretreated. If you use it in earlier lines of therapy, like after just the first or second relapse, it looks like it may actually be a little bit better than that.
But we need longer term data and more patients to be able to say that with confidence. Another thing that came out in an update about summer of last year was that a third of patients are still in remission at five years, which is remarkable for, you know, the patients in that clinical trial were multiple relapsed refractory. And that prompted a spate of news articles. And, you know, things on Google News about it was maybe talking about cure for myeloma. I think premature to be saying that we would be more comfortable saying something like that if we had like ten year data and we saw that there was a significant number of patients that definitely were not relapsing at that point. That is not something that we're really claiming.
But the thing to keep in mind is that if you're in remission for five years. Think about five years ago, we did not have Car-T commercially available for myeloma. So we can add myeloma treatment. A lot of these days is somewhat try to knock it down and keep it away as long as possible. And if you can kick the can down the road five years, who's to know what we might have five years from now? And maybe there's also combinations and things like that, or different ways of sequencing therapy that we can get to. What Doctor Silverman was talking about earlier, a is better tolerated than. So, it has fewer severe side effects. It does have a significant risk of the lower grade or milder side effects.
But terms of severe side effects, that's much less common. Unfortunately, it does not seem to work as well. The average remission with A is more about roughly a year or so. So we generally tend to use in the vast majority of our patients because we sort of figure if you're going to go to the trouble of doing Car-T, you might as well go out with a bang. And there's also, you know, now that we have other treatments for myeloma that are also quite effective, like bispecific antibodies, there's a less need to use Abecma, because the concern is that you may not be what we call fit or a good candidate for the, you know, for the car, which may have higher risk. Then maybe you try a less intensive therapy like bispecific rather than trying Abecma.
So we do not use Abecma very often anymore, but it still does have a role.
So the next thing was candidacy for Car-T. So you've relapsed after 1 or 2 lines of therapy. You've had the prior treatments we've talked about. And so you would meet the guidelines for where we would consider you to meet the disease eligibility for Car-T. But how about you as a person, what makes you eligible as a person for Car-T? So the one important thing we look at is your general health. So how are your heart lungs, liver, kidney. How are they working? Do you have a serious active infection that is needing ongoing treatment? So in terms of heart and lung, liver function, it's much more liberal than stem cell transplant. It's much less stringent. You know, we can, but you still have to have some modicum of reasonable health, because if you do get side effects, you know, you have to be able to make it through.
But, you know, for example, a normal cardiac, function is, we are willing to take much lower numbers and also for lung tests and, and for car T than we would for stem cell transplant for kidneys. We have done car T and patients who are on dialysis. And it can be done as successfully. We just have to modify the chemo a little bit, the lymphodepletion part. But we have done it successfully. Another question that comes up is age. Now age is definitely much easier with us in terms of car T than stem cell transplant. So once you get into your 70s, we're not that excited about doing auto transplants anymore. We can, but if you're really healthy in your early 70s, we we will still consider it. But we have done CAR T in people into their 80s.
Supposedly the national record of car T is in the early 90s. We we have not done that. But, I just want to say that age itself is not a barrier to car. T is really what your general health is and how what we call your energy and activity, what physicians call performance status, which is a terrible term to explain to patients. But basically it's can you do your activities of everyday life? Are you independently living? Can you get up and walk a couple of blocks? Can you do those sorts of things? If you can do those sorts of things, then you're probably going to be a candidate for car T, even if you're 78 or 81. Okay. Blood counts. So if your blood counts are really low coming into car T, there's a real risk that your blood counts could stay really low for a very long time afterwards.
So we like to see a reasonable white cell count, platelet count, that sort of thing coming into car T, you also have to have enough T cells because if you don't have enough T cells. Then we can't really collect your T cells to manufacture them. This is more a problem in lymphoma than it is in myeloma, but it does occasionally happen. Another thing is, are the T cells healthy? And that can sometimes depend on what your prior treatments were like. So some prior treatments will affect the health of your T cells. And in that situation we may say, well, it's probably should put off car T for another six months to a year until your T cells are a little bit more healthy. Before we try this CAR T. like stem cell transplant does require caregiver support.
This is not specialized medical trained. You know, nursing type support is basically someone who's there to support you through the treatment through especially the first month, if you get, you know, significant side effects like fevers and confusions can bring you back to the hospital, help you with your medications, take you back and forth to your appointments because you're not supposed to drive for the first month because of the risk of the confusion, things like that. It does not have to be the same person the whole time. It just needs to be a responsible adult. We have many patients who have a caregiver team. Someone does the weekday, someone does the evenings, someone does the weekday, someone does the weekend.
You know, things like that. Or someone, one person does a week, another person does another week. There's all sorts of variations on that that we have seen. Relocation if necessary. So we do have that if you have to stay within an hour of the car t center, some centers will expand that up to a little bit farther, but I think most places are roughly around an hour or so from the car t center. So you would have to relocate if necessary. If you're farther than that. Thankfully, we appreciate the assistance of the manufacturers that they will, as long as you meet the what are very reasonable financial guidelines, they will help support the relocation. And then you get to stay in the local hotel.
Usually there's two hotels along the waterfront, they're about a mile away that most of our patients stay at.
So apheresis, as I alluded to a little bit. So apheresis, for those who have not had stem cell transplant, this is what apheresis looks like. So basically an IV goes from you to a machine, the machine spins around, collects the T cells, and the rest of the blood returned to another IV. You may need what we call a temporary line that's placed by the radiologist under ultrasound guidance or collection. It kind of depends on how good your peripheral veins are. These are not like regular IVs for apheresis. These are very large, high caliber IVs. So it's the majority of patients do end up with a temporary line that's placed on the morning of collection. Then at apheresis. You're on the machine for a few hours.
It's done as an outpatient. And at the end of the day, they pull out the line, and then, it is very similar to stem cell collection, but there is no growth factor shots involved. And then we send the cells off to the manufacturer and they do their, you know, magic over the next 3 to 4 weeks. During that period, you may get what we call bridging therapy. Now this is optional and that is very individualized. This is optional treatment to control the myeloma while we're waiting for the cells to come back. Also, it's somewhat intuitive, but you have better control coming into Car-T. Your outcomes will be better. There's less disease for the Car T-cells that have to get rid of. The other thing is that you have a lot of disease coming into Car-T.
You're going to get a lot more inflammation, and you're going to be at risk for much more severe side effects. So there's two reasons for that. Better disease control. You get better responses and you get fewer major side effects. What you would get for bridging really depends on how much disease you have. And some people don't need bridging. And I would say the majority of patients we do generally get bridging to. But there are some patients that are still relatively early in their relapse. So that they can skip this. And in terms of what the bridging treatment would be, it really depends on what your prior treatments were. It's very individualized. And what we also look at like what genetic markers you have and that sort of thing in the myeloma to see what kind of treatments might be reasonable.
And again, you don't have to have a great response to get to go to Car-T. We just want some kind of reasonable disease control. This is not like stem cell transplant where we definitely prefer, you know, as low disease as possible before taking you to an auto transplant. The next step will be lymphodepletion chemotherapy. So it's low dose conventional chemotherapy. The typical regimen we use is two chemo drugs called fludarabine and cyclophosphamide. They're like traditional old fashioned what we call cytotoxic chemotherapy. But it's relatively low dose. Most patients do, you know, have maybe some mild nausea with it. But, it's given as an outpatient generally for three days in a row. Occasionally we will use a different drug called bendamustine.
That's a little bit easier on the kidneys. But this is sort of generally done as an outpatient, and it's generally pretty well tolerated. The idea behind this is not to knock down your myeloma. The idea for this is to make room in your immune system. So, knock down your immune system so that there's room for the car T cells to expand.
So cell infusion, so cell infusion that they're frozen cells and they cut. But it's a little bag. It's it's a much smaller bag than what you saw when you see what stem cell transplant. The cells are when they're frozen, they are frozen in DMSO to, you know, to help protect them during the freezing process. And when the cells are thawed and given to you, there is a little bit of DMSO. So that goes in. So there can be an unusual taste or odor. But this is such a small volume that most patients don't even notice it. But some patients do notice it and do get some nausea or something like that from it. We generally do our infusions here as an outpatient. It will depend on how your center is set up, whether they just infuse it as an outpatient or inpatient, but it just goes through your line for, for this, generally for our patients, we place a central line, what we call a PICC line.
So not a tunnel line in your chest, but a PICC line is a semi-permanent IV that goes into your upper arm and can stay there for weeks or even months. And then we and then the most important thing after cell infusion is close monitoring. We see our patients basically daily for the first two weeks, unless you're in the hospital and then in the hospital, you're, you know, obviously being seen hopefully at least but, you know, weekends, holidays doesn't matter. You know, I, we, we figure out it's that's part of that's one of my jobs is to figure out, make sure we have adequate coverage is 7365366 if it's a leap, and then this is where you would need the caregiver and staying in the local areas this period.
Now, the FDA used to have a strict policy that, you should stay in the local area for 30 days. They have since lifted that and updated to that. They recommend that you stay in the local area for minimum of two weeks. In our experience, we generally still recommend a month staying around here because people can still have side effects and not have really recovered yet after the first two weeks. Although the greatest risk of the fevers and confusion is in the first two weeks for the fevers, and for confusion is in the first 2 to 3 weeks. But, so it depends on how your center and how strict you know, they are. But we generally tell our patients expect to be up here for a month. But the FDA has lifted that mandatory requirement.
And so the major side effects of CAR T therapy, there's sort of four common categories. And then there's the rare but serious okay. So the first major categories is what we call cytokine release syndrome. And that's basically a fever inflammatory syndrome. The second one is what we call neurotoxicity where the inflammation affects the brain. And that comes across starts out as confusion. Then the other thing we worry about are as infections and then low blood counts are what's also called cytopenias. And then I'll go over some rare but serious toxicities that we can see after Car-T therapy.
So cytokine release syndrome basically it's an inflammatory syndrome with fever. Cytokines are the messenger molecules that T cells produce when they get activated. And then these this causes inflammation. And then you get a fever. Basically in most people it feels like you're getting the flu. You get fevers the T you can get chills body aches, you can get headaches. It typically occurs in the first two weeks. The average onset after car is around day seven right around that time frame. It is very rare to happen out of the blue after the first two weeks. It is it is extremely rare. So if you one thing a lot of people ask is what happened? So in the you know, when we when car T was still relatively new, we used to kind of hope that people got some fevers because that meant that the car T cells were working.
And, you know, we didn't want them to get too severe inflammation. And, you know, because then they could get really sick. But, it actually turns out that there's not a super strong correlation between getting the fevers and your response. So the car t can still work even if you don't get the fevers. So we, people ask about that a lot. So mild the low grade, you just get the fevers. That is very common. Probably 75% of patients will get fevers with Carvykti and similar with Abecma, just getting the fevers alone advanced what we call high grade CRS or inflammatory syndrome, where it affects your oxygen levels or blood pressure. That is not that common these days. We're talking less than 20% of the time in our experience that what you would see that, it is more common to get severe cytokine release syndrome if you have a lot of disease coming in and that kind of figures, because you have more burden there to cause more inflammation.
The treatment is that is if it's only mild and only lasts a day, we often just watch it and it will go away on its own. If it persists or it becomes more advanced, then we can get anti cytokine agents. The most common one that's used is called tocilizumab or Tosi. You can you can hear doctors or nurses talking about that and then steroids if necessary as well in more severe cases.
So the next one that can happen sometimes is the confusion. The. So good luck remembering how to say immune effector cell-associated Neurotoxicity syndrome is a name that a committee came up with. So apologize for that. It's called ICANS for short. It's basically when inflammation affects the brain and it causes confusion. This usually it's usually a relatively mild and some the sentence like something's off with your memory. You can't use your phone. You, you have a hard time finding words. Some loss of coordination can have weakness or tremors, gets more sleepy, have problems with attention, and especially your short term memory seems to be off in the severe cases. It can cause changes in your level of consciousness or even seizures.
This usually occurs in someone after they've already had cytokine release syndrome, usually a few days after that. Usually it happens in the first 2 to 3 weeks. It is exceedingly rare to get ICANS if you've never had the cytokine release syndrome. There is a standardized test that's used all around the country called the ICE score. ICE score. And it's basically a little mini quiz that you had to take. And there's like, you had to count backwards. You have to like, you know, be able to recognize and repeat things. You have to write a sentence. I personally think after a few days it's not a very good quiz because the patients have all memorized the questions, but, but is that's the standardized test.
And then depending how many points you miss, then that gives the severity, the grade of the confusion. It is significantly less common than the fevers in the current, depending on which study you look at. And the more current data, it's more like the risk is more. Around 10 to 20% of patients can get the confusion. And then severe confusion is much less is less than that. So, the treatment, if it's mild, we often just watch it initially. And if it persists or it becomes more advanced than we give people steroids. And there's also anti cytokine agents that we can use. The one that we typically use is called anakinra.
So infections is the next big category of things we worry about. So in the short term in the first month when you're immune suppressed from the lymphodepletion and your blood counts are low, you can get any kind of bacterial, fungal, viral, that sort of thing. However, even after the first month, even after your neutrophils and white count has recovered, you will be still at ongoing risk for infection. And that's because the Car-T is a, you know, quite immune suppressive, the T cells are very good at killing the plasma cells that cause the myeloma. However, they will also kill all your good plasma cells that also express the target. And because of that, you will not have antibody responses to infections for quite a bit period of time.
That's particularly important for things like respiratory infections or infection or viral infections. Okay. You know when you have neutrophils you have a reasonable defense against bacterial most bacteria and as well as fungal infections. But the lack of antibodies and if your immunoglobulin the IG level is quite low. We often will recommend a replacement antibody for what we call it. IVIg, or intravenous immunoglobulin. Another thing that people ask a lot about are vaccines. So the general recommendation is to consider vaccines. You don't have to be revaccinated like you do in transplant where you do the whole childhood thing with, you know, starting even polio and things like that for our, our center, our practice is to recommend the vaccine for flu, pneumonia and Covid.
Looking at three to starting roughly around 3 to 6 months. After car T with when big caveat if you have not recovered your B cells by that point and you're native, what your level is without replacement is super low. The likelihood you respond to that vaccine is not great. So then that that's you don't have B cells. The chances and you have plasma cells, you're probably not going to make much of an antibody response to that vaccine. So then that becomes a little bit more of a discussion with your physician or your provider, whether you know you want to try for the vaccine, there is a theoretical benefit that the vaccine may stimulate other parts of the immune system like your T cells. But they have looked at they have done studies and the vaccine responses.
If you, if your B cells have not recovered and your antibody levels are really are not the best, unfortunately. So we tell patients that even a year or two later after car t, they need to be careful. And if they get, you know, symptoms of an infection, they do need to come in and get evaluated. And low antibody levels can be treated with IVIg replacement, low blood count that you can get neutrophils for growth factor shots and for red cells you can get transfusion and platelets. You can get transfusions and other medications. And then if someone's to stimulate the platelet growth when concern is that if your blood counts are go really low, then you may need a stem cell boost. And to help stimulate your blood counts recover.
So it's like an auto transplant without the chemo. Rare but serious side effects. So the this is the greatly feared one. The movement and neurocognitive toxicity the BCMA target is also expressed in other parts of the brain. This is what we call an on target off tumor effect. And this can cause facial palsy, tremors and in severe cases, cognitive changes or even Parkinson's like syndromes. This is associated with a rapid expansion of T cells, and the treatment depends on what symptom you have and the severity. Thankfully this is rare. Palsies can occur in maybe 5 to 10% of patients. The the Parkinson's type stuff. That's less than 5% of patients that will get that. Colitis. So normally plasma cells are also found along the lining of your intestine.
And that can cause so when the cells go there, they can trigger this inflammation along your colon that results in diarrhea and inflammation. The colon what we call colitis. And this would then be treated or as we treat inflammatory bowel disease. So like people with all sorts of colitis or Crohn's. And then hemo phagocytic syndrome is a very rare severe inflammatory syndrome that you can get after Car-T. And then you would also be at risk for second cancers. And that's in part because patients who get cancer get chemotherapy, and chemotherapy can damage their normal cells. And then it can also, it suppresses your immune system. And your immune system normally helps prevent cancer in terms of car T and autologous stem cell transplant.
So autologous transplant is used as part of initial therapy generally. So you get your initial therapy which these days is typically a four drug induction. And then you get a transplant and then you get maintenance therapy. Its role as being challenged for standard risk disease. If you have an excellent response to induction, what we call MRD negative minimal residual disease, negative. CAR T, on the other hand, is approved in the relapse setting. There are clinical trials ongoing to compare auto transplants versus car T as consolidation of your first response. But that is an area of research. Car T, generally speaking, is better tolerated than transplant. There's less short term toxicity. You don't get the severe nausea, vomiting, diarrhea.
You're not in the hospital for two weeks. But auto transplant is much more predictable. You know everybody gets the nausea vomiting diarrhea by around day 3 to 5. Everyone's white. Count down at the bottom between days 5 to 10. You know it's much more predictable. Car t some patients will fly through and wonder what the big deal was. And they never had a side effect, never had a fever. And then some patients and Car-T can get the severe neurotoxicity and they can get quite sick. And so it's a huge variability with car t the role of delayed auto transplant at first relapse or second transplants that we used to do that is starting to go away with car T, a lot of these patients are instead going to car T rather than doing a late auto transplant or a second auto transplant.
How about CAR T and bispecific antibodies? So in terms of logistics, CAR T is one time therapy. Bispecific is ongoing therapy. Car T have to go to a treatment center. On the other hand bispecific is typically available locally. Car-T has a manufacture time. While the bispecific is right there, it's what they call off the shelf and car. There's more caregiver support needs than what in terms of myeloma control. If you look across the studies, there are not any randomized head to head studies yet. So you're looking across studies and looking at like some registry analyses. It looks like CAR T responses are probably somewhat better, but bispecific is still far better than the traditional therapies that are out there.
And nobody's really quite sure how much CAR T might be better than bispecific, or if it really is because we don't have a randomized study yet. Side effects are definitely more with car T than by. In terms of the fevers and the confusion. Bispecific, though does have a significant risk of infections. And then the cost, there's a high upfront cost with CAR T. Bispecific You look, if you do a year's worth of bispecific therapy then you're approaching the cost of car T. One question that does come up is whether you might be interested in both. And they have done analyzes of this. And it looks like the outcomes are better if you do CAR T before you do bispecific. It's hard to go straight from bispecific to CAR T, but if you had CAR T a year or two ago, you can go to bispecific without problem.
The issue is that if you're actively relapsing on bispecific and go straight to car T, there's a concern that your T cells may not be very healthy. There's a concern that those T cells have been suppressed, or for whatever reason, your myeloma has now become resistant to T cell mediated therapy because the way that bispecific antibodies work is basically activating your T cells to try to kill the myeloma cell.
So in terms of improving car T, we're almost at the end now. One area of great interest is target binding. So the commercially available, the two commercially available car T's both target BCMA, which is a marker that's expressed on myeloma protein. So one idea out there is to try to have what we call L target. So GPRC5D, that's the target that's targeted by map which is when the bispecific antibodies there are other bispecific antibodies like to map that target BCMA. There's also interest in making what we call dual targeted car T. So maybe the reason CAR T stops working is that the plasma cell loses expression of the target. So if you hit two targets at the same time, that's less to become an issue.
So there are studies of interest where you combine two targets on the same car T cell. And then there's ways that you can change the way that the T cell gets activated. And what we call armored car T's. Those are probably earlier on in development. And there's been a lot of talk about what we call off the shelf or universal donor. And that's where they get donor T cells and make car T out of the donor T cells. That's still a lot of people have tried. That's still kind of in the early stages still. And then the new hot thing out there is what we call in vivo expansion, which is basically they take the they have the DNA or actually the sometimes it's RNA, but it's they actually just give that to you like a drug.
And then it gets into your T cells in your body and makes the car T cells in your body. And so it's off the shelf. There's no delay. And it's it's the next cool thing out there. It's still early, but that's a so this goes to what we call about target regulation. So now cilta- cel has two different binding domains compared to ide-cel which only has one. And in silk to sell or die. They're actually derived from the llama which is a member of the camel family. I always thought it was a horse, but now, anito-cel is probably. Hope it may. It's at the FDA for approval and it has a different binding domain than the the other two. It's a synthetically made binding domain. And in the early, you know, sort of the earlier studies, it hasn't been in a what we call a phase three really big study yet.
It looks like it has, you know, good efficacy, but maybe somewhat less side effects compared to is that's going to hold up over the long term. We don't really know yet. We also don't know yet how the efficacy or how well it works is going to turn out. Compared to there's also GPRC5D targeted CAR T, and the one that's furthest along in development is arlocabtagene. And then there's also what we call dual targeted CAR T, and at OHSU We have studies we've had we either have active studies or opening studies or had studies on anito- cel as well as arlo-cel as well as a we have a dual targeted one that's about to open as well. And finally, I think I've run out of time and the questions. So CAR T stands for chimeric antigen receptor where we take your T cells and make them into heroes to fight the myeloma.
Doc is the official therapy dog at the Knight Cancer Institute, and his official title is Director of Cuddles. I did not come up with that.